Send to

Choose Destination
Oncology (Williston Park). 1998 Jan;12(1):99-106; discussion 106, 112, 115.

Differentiated thyroid carcinoma: risk group assignment and management controversies.

Author information

Department of Head and Neck, Roswell Park Cancer Institute, Buffalo, New York, USA.


In this review, we provide a framework for clinical decision-making in the treatment of differentiated thyroid cancer. The clinical discussion and treatment recommendations are relevant to an adult population (> 16 years of age). The natural history, pathogenesis, diagnostic tools, and treatment controversies in the management of this disease are explored. The roles of radioiodine therapy and thyroid-stimulating hormone (TSH) suppression and the treatment of locoregional disease are reviewed. This discussion provides a comprehensive assessment of management and treatment issues in differentiated thyroid cancer.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for UBM Medica LLC
Loading ...
Support Center